CCT369260

Product Data Sheet

Cat. No.:	HY-129188
CAS No.:	2647503-57-7
Molecular Formula:	$C_{24}H_{31}ClF_2N_6O_2$
Molecular Weight:	508.99
Target:	Bcl-2 Family; Molecular Glues
Pathway:	Apoptosis; PROTAC

Storage:

	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

SOLVENT & SOLUBILITY

In Vitro	DMSO : 300 mg/mL (589.40 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	1.9647 mL	9.8234 mL	19.6468 mL
	5 mM	0.3929 mL	1.9647 mL	3.9294 mL
	10 mM	0.1965 mL	0.9823 mL	1.9647 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	CCT369260 (compound 1) is an orally avtive B-cell lymphoma 6 (BCL6) inhibitor with anti-tumor activity. CCT369260 (compound 1) exhibits an IC$_{50}$ of 520 nM[1].
IC$_{50}$ & Target	IC50: 520 nM (BCL6)[1].
In Vivo	CCT369260 (compound 1, 15 mg/kg, po, single dose) significantly inhibits BCL6 in OCI-Ly1 DLBCL xenograft model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	OCI-Ly1 DLBCL xenograft model (female SCID mice)[1].
Dosage:	15 mg/kg.
Administration:	PO, single dose.
Result:	Decreased the levels of BCL6 in the tumor observed up to 10 h after administration.

Animal Model:	Female Balb/C mice[1].
Dosage:	1 mg/kg iv and 5 mg/kg po (Pharmacokinetic Analysis).
Administration:	IV and PO
Result:	Demonstrated moderate clearance (CL 20 mL min^{-1} kg^{-1}) with mean oral bioavailability of 54%.

REFERENCES

[1]. Benjamin R Bellenie, et al. Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders. J Med Chem. 2020 Apr 23;63(8):4047-4068.